Ryan Cappelli
@Prosight Management, Lp
Latest period2024 - Q3ReportedManaged Assets$406.357MTotal holdings45
Assets growth rate21.46%Assets growth rate (2-Q avg)7.27%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Prosight Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 45 positions.
Assets under management
The assets under management (AUM) of Prosight Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 406.357M in assets, with a quarterly growth rate of 21.46% and a 2-quarter average growth rate of 7.27%. The portfolio is managed by Ryan Cappelli, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
KURAKura Oncology Inc
| 3.4% | $13.778M 705,109 shares@ $19.55 avg price | Increased 11.94% |
SDGRSchrodinger Inc
| 3.2% | $12.985M 700,000 shares@ $18.55 avg price | Increased 89.57% |
ZYMEZymeworks Inc
| 2.84% | $11.516M 917,599 shares@ $12.55 avg price | Decreased -22.23% |
ACCDAccolade Inc
| 2.66% | $10.786M 2.802M shares@ $3.85 avg price | Increased 88.09% |
DXCMDexcom Inc
| 2.64% | $10.726M 160,000 shares@ $67.04 avg price | Increased 224.44% |
SNDXSyndax Pharmaceuticals Inc
| 2.63% | $10.666M 554,103 shares@ $19.26 avg price | Increased 0.47% |
IMVTImmunovant Inc
| 2.6% | $10.549M 370,000 shares@ $28.51 avg price | Increased 13.85% |
CYTKCytokinetics Inc
| 2.51% | $10.175M 192,700 shares@ $52.8 avg price | Decreased -16.21% |
JANXJanux Therapeutics Inc
| 2.3% | $9.313M 205,000 shares@ $45.43 avg price | New Position |
PRTAProthena Corp Plc
| 2% | $8.088M 483,467 shares@ $16.74 avg price | Increased 68.5% |